miR-671-5p Blocks The Progression Of Human Esophageal Squamous Cell Carcinoma By Suppressing FGFR2
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 15 (9) , 1892-1904
Abstract
Esophageal cancer is the eighth most common malignant tumor worldwide, of which esophageal squamous cell carcinoma (ESCC) is the dominant histological subtype. A drug shortage for ESCC therapy triggered us to explore the roles of fibroblast growth factor receptor 2 (FGFR2) and its upstream regulator miR-671-5p in ESCC progression. We compared the levels of FGFR2 and miR-671-5p between human ESCC tissues and their matched normal esophageal tissues and found an association between higher levels of FGFR2 and lower levels of miR-671-5p in ESCC tissues. High levels of FGFR2 resulted in the activation of the ERK and AKT pathways and a promotion of ESCC progression. High levels of miR-671-5p specifically reduced the expression of FGFR2 and suppressed ESCC progression in both in vitro and in vivo models. Therefore, suppressing FGFR2 and enhancing miR-671-5p expression may be the right approaches for ESCC therapy.Keywords
This publication has 61 references indexed in Scilit:
- Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinomaCell Death & Disease, 2013
- Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiencyNature Communications, 2013
- Down-Regulation of the Oncogene Cyclin D1 Increases Migratory Capacity in Breast Cancer and Is Linked to Unfavorable Prognostic FeaturesThe American Journal of Pathology, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targetsOncogene, 2010
- FGFR2-related pathogenesis and FGFR2-targeted therapeutics (Review)International Journal of Molecular Medicine, 2009
- Origins and Mechanisms of miRNAs and siRNAsCell, 2009
- MicroRNAs: Target Recognition and Regulatory FunctionsCell, 2009
- Involvement of Human Micro-RNA in Growth and Response to Chemotherapy in Human Cholangiocarcinoma Cell LinesGastroenterology, 2006
- The activities of cyclin D1 that drive tumorigenesisTrends in Molecular Medicine, 2004